top of page


1.Sun Pharmaceuticals

Market Cap: 1.66LCr

P/E ratio: 68.88

It is India's largest pharmaceutical company and the world's fourth-largest. It is India's largest multinational pharmaceutical company. It first opened its doors in 1983. Mr. Dilip Shanghvi, who is also the MD of Sun Pharmaceuticals, founded the company. With the acquisition of Ranbaxy in 2014, Sun became India's largest pharmaceutical company, the largest Indian pharmaceutical company in the United States, and the world's fifth-largest specialty generics company. Ranbaxy Laboratories, Sun Petrochemical Pvt. Ltd, Sun Ophthalmic Inc, Alkaloida Chemical Company Zrt, and Chattem Chemicals Inc are some of the company's subsidiaries. It sells low-cost medicines in more than 150 countries on six continents.

2. Divis Laboratories

Market Cap: 1.07LCr

P/E ratio: 57.23

Divi's Laboratories began as Divi's Research Centre in 1990. Initially, the company focused on developing commercial processes for the production of APIs and intermediates. In 1994, Divi's Research Centre renamed itself Divi's Laboratories Limited to signal its intention to enter the API and intermediates manufacturing business. On February 17, 2003, the company went public with an initial public offering (IPO). The company opened a research centre in Hyderabad in 2010.

Divi's was recently named one of the top three API manufacturers in the world, as well as one of the top API companies in Hyderabad. Divi's is an Indian public limited company with a revenue of INR 5500 crores ($780 million) for the fiscal year 2018-19.

3. Dr. Reddy's Lab

Market Cap: Rs 86.10TCr

P/E Ratio: 39.75

Anji Reddy founded the company in 1984. Dr. Reddy's produces and sells a wide range of pharmaceuticals in India and around the world. Over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacturing, diagnostic kits, critical care, and biotechnology products are among the company's offerings. It has a revenue of INR 144.36 billion and is India's fifth-largest pharmaceutical company. Canagliflozin is one of the company's most well-known products. Ramipril, Ibuprofen, Naproxen, Atorvastatin, Nizatidine, Naproxen Sodium, and other drugs are used to treat high blood pressure.

4.Cipla Ltd

Market Cap: 72.90TCr

P/E Ratio: 32.63

Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical company. Cipla primarily develops medicines for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical conditions. Khwaja Abdul Hamied established 'The Chemical, Industrial & Pharmaceutical Laboratories' in Mumbai in 1935. On July 20, 1984, the company's name was changed to 'Cipla Limited.' Cipla has a revenue of 3.5 billion dollars and employs over 22,036 people. Invagen Pharmaceuticals is one of Cipla's subsidiaries. They are the world's largest producer of antiretroviral medications.

5. Lupin

Market Cap: 53.67TCr

P/E Ratio: 46.64

Lupin Limited, based in Mumbai, Maharashtra, India, is an Indian multinational pharmaceutical company. It is one of the world's most profitable generic pharmaceutical companies. Paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis are among the company's key focus areas. Desh Bandhu Gupta, a professor of chemistry at BITS-Pilani in Rajasthan, founded Lupin in 1968. Gupta moved to Mumbai in the 1960s to work on his business, for which he had borrowed Rs 5000 from his wife to start. The company's drugs are available in 70 countries, including advanced markets like the United States, Europe, Japan, and Australia, as well as emerging markets like India, the Philippines, and South Africa, to name a few.

Recent Posts

See All

Trade on 3rd April

Pay 99 rs on paytm/gpay at +918169143442 To get index/stock options, intraday futures , intraday equity with entry, sl and target for 3rd april. ( 1 day only) To get same content for free click on im

A small cap can turns into multibagger

Buy Sumedha 50 % @ 51 50 % @ 45 Stoploss 35 Target 97 - 155 -320 Reason to buy - stock has given monthly quaterly & yearly breakout ARE YOU INTERESTED IN BUYING UNLISTED SHARES? CONTACT US ON +918169


bottom of page